Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
Norman Wasel
Diamant Thaçi
Lars E. French
Curdin Conrad
Yves Dutronc
Gaia Gallo
Lovisa Berggren
Jean-Philippe Lacour
10.6084/m9.figshare.12179274.v1
https://adisjournals.figshare.com/articles/figure/Ixekizumab_and_Ustekinumab_Efficacy_in_Nail_Psoriasis_in_Patients_with_Moderate-to-Severe_Psoriasis_52-Week_Results_from_a_Phase_3_Head-to-Head_Study_IXORA-S_/12179274
<p>The above Summary Slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.<b>
</b></p>
2020-05-11 10:17:25
Ixekizumab
Nail psoriasis
Psoriasis
Ustekinumab